Clinical Trials

31 enrolled 13 charts

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

NCT00792142 2021-08-19

Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

45 enrolled 8 charts

Multiple Myeloma, Neurotoxicity Syndromes, Neoplasms, Plasma Cell

NCT00469209 2020-09-24

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

60 enrolled 7 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00084747 2020-08-17

Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma

30 enrolled 7 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00985907 2020-06-17

DMV

Phase 1/2 Terminated

13 enrolled 8 charts

Multiple Myeloma, Patient Participation, Neoplasms, Plasma Cell

NCT01438177 2020-02-24

Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma

Phase 2 Terminated

11 enrolled 9 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00568880 2020-02-07

Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

25 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00948922 2019-09-18

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

124 enrolled 13 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02188537 2019-06-26

Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma

34 enrolled

Neoplasms, Plasma Cell

NCT01164709 2019-05-15

Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

DermatologicLymphoidOther hematologic neoplasmPlasma cell

18 enrolled

Congenital Abnormalities, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, Follicular, Multiple Myeloma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell

NCT01191060 2019-04-18

IFM/DFCI2009

Phase 3 Completed

700 enrolled

Disease Progression, Neoplasms, Plasma Cell

NCT01440582 2019-03-04

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

77 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01554852 2018-06-11

Myeloma XI

Phase 3 Unknown

4,420 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01315873 2018-02-07

Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

Phase 2 Terminated

24 enrolled 3 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00744354 2018-01-18

Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Terminated

32 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01332617 2017-12-29

Phase II Study of Simvastatin for Relapsed/Refractory Myeloma

Phase 2 Withdrawn

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00523848 2017-02-23

Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma

46 enrolled 8 charts

Phase EARLY_PHASE1 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01171092 2017-01-11

A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma

21 enrolled

LymphoidPlasma cell

Lymphoma, Neoplasms, Plasma Cell

NCT00504101 2016-12-15

Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma

Phase 1 Withdrawn

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00458822 2016-08-10

Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis

40 enrolled 5 charts

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00983346 2016-07-11

Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients

Phase 2 Terminated

17 enrolled 5 charts

Smoldering Multiple Myeloma, Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell

NCT00111748 2015-10-06

UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients

Phase 3 Completed

180 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02027220 2014-01-06

Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma

Phase 2 Unknown

60 enrolled

Neoplasms, Plasma Cell

NCT00288028 2013-11-19

Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant

15 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00258245 2013-04-29

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

5 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00428545 2013-02-12

Bevacizumab and Bortezomib in Patients With Advanced Malignancy

104 enrolled

LymphoidPlasma cell

Lymphoma, Neoplasms, Plasma Cell

NCT00237627 2012-05-18

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

BreastDermatologicGynecologicLymphoidOther hematologic neoplasmPlasma cell

107 enrolled

Congenital Abnormalities, Carcinoma, Ovarian Epithelial, Blast Crisis, Breast Neoplasms, Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Leukemia, Hairy Cell, Leukemia, Mast-Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Ovarian Neoplasms, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Breast Neoplasms, Male, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Intraocular Lymphoma

NCT00006362 2011-08-03

PS-341 in Treating Patients With Advanced Cancer

LymphoidOther hematologic neoplasmOther neoplasmPlasma cell

Immunoglobulin Light-chain Amyloidosis, Burkitt Lymphoma, Leukemia, Leukemia, Hairy Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT00609167 2011-05-17

Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

63 enrolled 15 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00478075 2011-05-11

Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

50 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00093028 2010-07-02

Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II

Phase 3 Completed

315 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00358020 2006-12-04

Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients

30 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00378755 2006-09-22

Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM

Phase 2 Unknown

62 enrolled